JANPIX
Janpix is discovering and developing inhibitors of Signal Transducer and Activator of Transcription (โSTATโ) proteins. Most members of this family of transcription factors have been known for some time and their relevance in certain cancers, in particular for STAT3 & STAT5, validated. Inhibiting the function of STAT proteins though has been very challenging thus far and Janpix developed new chemistry to address this complex problem.
JANPIX
Industry:
App Discovery Biotechnology Therapeutics
Founded:
2013-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.janpixbio.com
Total Employee:
1+
Status:
Active
Total Funding:
27.67 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Office 365 Mail Microsoft Azure DNS GoDaddy DNS
Similar Organizations
Cellugy
Cellugy operates as a biotechnology startup.
iNNOHEALTH technology solutions
iNNOHEALTH operates as an health technology start up
Nitroterra
Nitroterra operates as a biotechnological startup.
Current Advisors List
Current Employees Featured
Founder
Investors List
Official Site Inspections
http://www.janpixbio.com
- Host name: 172.67.193.165
- IP address: 172.67.193.165
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Janpix"
Janpix - Crunchbase Company Profile & Funding
Janpix is discovering and developing inhibitors of Signal Transducer and Activator of Transcription (โSTATโ) proteins. Most members of this family of transcription factors have been known for โฆSee details»
Janpix Company Profile 2024: Valuation, Investors, โฆ
Janpix General Information Description. Developer of ultra-selective STAT inhibitors designed to treat hematological tumors and glioblastomas. The โฆSee details»
Janpix Company Profile | Management and Employees List
Janpix Profile and History. Janpix Inc was launched in 2017 following seed financing by Medicxi. The Company's aim is to advance the discovery and clinical development of selective STAT โฆSee details»
U of T startup Janpix receives $22 million in funding to โฆ
Oct 11, 2017 Professor Patrick Gunning, a medicinal chemist whose lab at the University of Toronto is revolutionizing how cancer-killing drugs are produced, has signed a $22-million investment deal for Janpix, an oncology-focused startup โฆSee details»
Janpix - Overview, News & Similar companies | ZoomInfo.com
Oct 6, 2020 Janpix contact info: Phone number: (617) 956-2803 Website: www.janpixbio.com What does Janpix do? Janpix Inc was launched in 2017 following seed financing by Medicxi. โฆSee details»
Janpix Holdings, Inc. (Janpix Holdings, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ โฆ
Abstract STAT5 is a member of the signal transducer and activator of transcription family of proteins and is widely recognized as an oncogenic master regulator of hematological โฆSee details»
Janpix Company Profile - Office Locations, Competitors, Revenue โฆ
Janpix is a biotechnology company discovering and developing inhibitors to help patients suffering from cancer. It provides a pipeline of STAT (signal transducer and activator of transcription) โฆSee details»
Janpix - Company Profile - Tracxn
Nov 5, 2024 Janpix ranks 129th among 250 active competitors. 102 of its competitors are funded while 60 have exited. Overall, Janpix and its competitors have raised over $7.29B in funding โฆSee details»
Janpix Inc., co-founded by Patrick Gunning, launches โฆ
Breadcrumb. News Room; Janpix Inc., co-founded by Patrick Gunning, launches with $22 million in funding to advance cancer therapiesSee details»
Janpix Inc. - BioCentury Company Profiles - BCIQ
Apr 13, 2023 Janpix Inc. - BioCentury Company Profiles for the biopharma industrySee details»
Janpix Management Team - CB Insights
Janpixbio.com. Overview & Products; Financials; People; Executives 1. Board of Directors 1. Janpix Management Team1 Team Member. ... leadership, strategy and general management โฆSee details»
Janpix Announces $10 Million Series B Financing to Advance STAT โฆ
Oct 7, 2020 For more information visit www.janpixbio.comMedia Contact: Ryo Imai Burns McClellan +1-212-213-0006, [email protected]. CAMBRIDGE, Mass., Oct. 07, 2020 โฆSee details»
U of T startup Janpix receives $22 million in funding to advance โฆ
Professor Patrick Gunning, a medicinal chemist whose lab at the University of Toronto is revolutionizing how cancer-killing drugs are produced, has signed a $22-million investment โฆSee details»
Our Client Janpix Ltd Presents Their Program Updates at the โฆ
Jun 15, 2020 For more information visit www.janpixbio.com . Media Contact: Ryo Imai Burns McClellan +1-212-213-0006, [email protected]. Previous. Next. ... A seasoned drug โฆSee details»
Janpix Announces $10 Million Series B Financing to Advance
CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Janpix Inc., a biotechnology company developing monovalent small molecule protein degraders of STAT...See details»
Upgrading with a $10M series B, Janpix advances its protein
Oct 9, 2020 Janpix Inc., of Cambridge, Mass., has raised a $10 million series B designed to progress its monovalent small-molecule protein degraders of STAT3 and STAT5 into final โฆSee details»
Janpix Announces $10 Million Series B Financing to ... - Markets โฆ
CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Janpix Inc., a biotechnology company developing monovalent small molecule protein degraders ...See details»
Janpix Announces $10 Million Series B Financing to Advance
Oct 7, 2020 Janpix has identified small molecule degraders of STAT3 and STAT5 that show therapeutic potential in a number of hematological and solid tumors. Janpix is focused on โฆSee details»
Potent Preclinical Antitumor Activity Demonstrated by Janpixโs ...
CAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Janpix Inc., a biotechnology company developing monovalent small molecule protein degraders as novel therapeutics, โฆSee details»
Potent Preclinical Antitumor Activity Demonstrated by
CAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Janpix Inc., a biotechnology company developing monovalent small molecule protein degraders as novel...See details»